Drugs / TELAZORLIMAB
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03568162 | May 2018 → Aug 2020 | atopic eczema | Ichnos Sciences SA | Completed | Met primary |
| Phase 2 | NCT02683928 | Mar 2016 → Jun 2017 | atopic eczema | Ichnos Sciences SA | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-10-19 | Glenmark Pharmaceuticals Ltd. India | Results Data on Glenmark’s GBR 830, First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody in Development for Treatment of Atopic Dermatitis, to be Presented at the Fall Clinical Dermatology Conference glenmarkpharma.com ↗
Mahwah, NJ; October 18, 2018 – Glenmark Pharmaceuticals, a global pharmaceutical company, today announced that encore data from a Phase 2a, proof-of-concept study of GBR 830, an investigational treatment in development for moderate-to-severe atopic dermatitis (AD), will be presented at the Fall Clinical Dermatology Conference in Las Vegas. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-10-19 | Glenmark Pharmaceuticals Ltd. India | Data on Glenmark’s GBR 830, First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody in Development for Treatment of Atopic Dermatitis, to be Presented at the Fall Clinical Dermatology Conference glenmarkpharma.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TELAZORLIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594546 ↗ |
| Known as | GBR 830 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02683928 ↗ |
| Known as | ISB 830 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03568162 ↗ |
| Action | Inhibit | “Tumor necrosis factor receptor superfamily member 4 antagonist” CHEMBL4594546 ↗ |
| Modality | Monoclonal antibody | “GBR 830 is a humanized mAb against OX40” PMID 30738171 ↗ Feb 2019 |
| Route | Intravenous | “administered intravenously (IV) four weeks apart.” NCT02683928 ↗ |
| Target | TNFRSF4 | “Tumor necrosis factor receptor superfamily member 4 antagonist” CHEMBL4594546 ↗ |